Lyra Therapeutics, Inc. (LYRA) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$31.02M | +67.8% |
| 2024 | -$96.35M | -43.5% |
| 2023 | -$67.12M | -19.2% |
| 2022 | -$56.31M | -29.1% |
| 2021 | -$43.62M | -96.4% |
| 2020 | -$22.21M | -34.4% |
| 2019 | -$16.52M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$31.02M | +67.8% |
| 2024 | -$96.35M | -43.5% |
| 2023 | -$67.12M | -19.2% |
| 2022 | -$56.31M | -29.1% |
| 2021 | -$43.62M | -96.4% |
| 2020 | -$22.21M | -34.4% |
| 2019 | -$16.52M | — |